Clinical trials: Zoledronic acid
Urologic Neoplasms
Zoledronic Acid With Intermittent Hormonal Therapy in Patients With Prostate Cancer
Primary: To determine the duration of use of zoledronic acid in improving Bone mineral density in patients with prostate cancer who are on hormones intermittently.
- Trial name
- NCT00226954
- Testing
- zoledronic acid
- Where
- United States
- Volunteers
- 23 people
- Sponsor
- Stanford University
HIV Infections
Efficacy And Security Of Annual And Biennial Zoledronic Acid For Osteoporosis Treatment In An HIV-Infected Patients' Cohort
The purpose of this project is to determine the incidence of osteoporosis in the investigators' population of HIV-infected patients and to assess the efficacy and security of zoledronic acid, whose efficacy in post-menopausal…
- Trial name
- NCT00795483
- Testing
- Zoledronic acid, Lifestyle modifications
- Where
- Spain
- Volunteers
- 33 people
- Sponsor
- Germans Trias i Pujol Hospital
Primary Hormone Receptor Negative Breast Cancer in Premenopausal Women
A Study of Zoledronic Acid in the Prevention of Cancer Therapy-induced Bone Loss
Breast cancer and osteoporosis are two of the most frequent diseases in women. Estrogen may be associated with bone loss and the risk of breast cancer because of its potent effects on the mitotic activity of breast epithelium and…
- Trial name
- NCT00333229
- Testing
- Zoledronic Acid
- Where
- Germany
- Volunteers
- 11 people
- Sponsor
- Novartis Pharmaceuticals
Metastatic Prostate Cancer, Bone Metastasis
Duration of Suppression of Bone Turnover Following Treatment With Zoledronic Acid in Men With Metastatic CRPC
Bone is the most common site of metastases in prostate cancer and bone complications cause substantial morbidity to this population.
- Trial name
- SubDueP (NCT01062503)
- Testing
- Zoledronic acid
- Where
- Canada
- Volunteers
- 48 people
- Sponsor
- University Health Network, Toronto
Bone Metastases
Study of Denosumab vs. Zoledronic Acid to Treat Bone Metastases in Men With Hormone-refractory Prostate Cancer
The purpose of this study is to determine if denosumab is non-inferior to zoledronic acid (Zometa®) in the treatment of bone metastases in men with hormone-refractory prostate cancer
- Trial name
- NCT00321620
- Testing
- zoledronic acid, denosumab
- Volunteers
- 1,904 people
- Sponsor
- Amgen
Multiple Myeloma and Plasma Cell Neoplasm
Zoledronate With or Without Thalidomide in Treating Patients With Early Stage Multiple Myeloma
RATIONALE: Zoledronate may prevent bone loss and stop the growth of cancer cells in bone. Thalidomide may stop the growth of cancer cells by blocking blood flow to the cancer.
- Trial name
- NCT00432458
- Testing
- Thalidomide, zoledronic acid
- Where
- 4 sites in United States
- Volunteers
- 68 people
- Sponsor
- Mayo Clinic
Osteoporosis
Step-down Therapy After Long-term Osteoporosis Treatment
Maintaining bone mineral density (BMD) after discontinuing denosumab (Prolia) is a major clinical challenge, as rapid bone loss commonly occurs when treatment is stopped, especially after more than three years of use.
- Trial name
- NCT07281586
- Testing
- zoledronate, Denosumab De-escalation
- Where
- Taiwan
- Volunteers
- 44 people
- Sponsor
- National Taiwan University Hospital